What Sofar does

Sofar S.p.A. is an Italian pharmaceutical manufacturer, founded in 1968 and headquartered in Bologna, that has historically developed and produced its own line of products including dietary supplements and medical devices. Effective February 1, 2023, the company underwent a partial demerger (scissione parziale) whereby its commercial branch — including customer relationships, product brands, and digital properties — was transferred to its controlling parent company, Alfasigma S.p.A.

Following this restructuring, Sofar S.p.A. continues to operate as a legally distinct entity but is now dedicated exclusively to pharmaceutical production and Contract Development and Manufacturing Organization (CDMO) services for third-party pharmaceutical clients. The company's business model has therefore shifted from an integrated branded-products manufacturer to a pure B2B contract manufacturer operating under the Alfasigma S.p.A. corporate umbrella.

The entity is structured as an Italian private limited company (S.p.A.) with a single headcount band of 251–500 employees and no publicly disclosed revenue, pricing model, or product-level information in the available sources. Core technology is centered on pharmaceutical manufacturing capabilities rather than software, AI, or digital platforms, and the company has no disclosed marketing or distribution channels, patents, awards, partnerships, or leadership team details beyond a single CEO reference.

Name

Sofar

Legal name

Sofar S.p.A.

Website

https://sofarfarm.it

Company type

Private

Founded year

1968

Operating status

Operating

Headcount range

251–500 employees

Short description

Sofar S.p.A. is an Italian pharmaceutical CDMO and subsidiary of Alfasigma S.p.A., focused exclusively on contract manufacturing and production services for pharmaceutical clients following a February 2023 partial demerger from its parent.

Ownership category

akta.pro rank

Product category

Pharmaceutical Contract Manufacturing

NAICS

Pharmaceutical and Medicine Manufacturing (3254)

SIC

Pharmaceutical Preparations (2834)

akta.pro primary industry

Drug Substance–Drug Product Integrated CDMO (HLAGABAG)

Keywords

• Pharmaceutical manufacturing
• Contract development manufacturing
• CDMO services
• Drug production services
• Pharmaceutical contract services

Headquarters

HQ city

Petaluma

HQ country

United States

HQ region

North America

Offices1 record

Markets served

GTM type

B2B

Offering type

Services

Cost components

Personnel, Operations, Supply Chain, Technology or R&D

Core offering

Sofar S.p.A. operates as a pharmaceutical Contract Development and Manufacturing Organization (CDMO), providing dedicated production and contract manufacturing services to pharmaceutical industry clients. Following a partial demerger effective February 1, 2023, the commercial branch was transferred to parent company Alfasigma S.p.A., and Sofar S.p.A. now focuses exclusively on production and CDMO activities.

Product overview

No product information available in the provided sources. The available source indicates that Sofar S.p.A. operates as a production and Contract Development and Manufacturing Organization (CDMO), but no specific products, brand names, or service offerings are detailed in the aggregated content.

Differentiator

Problem solved

Functional benefit

Products and services

• Pharmaceutical CDMO and Production Services Contract Development and Manufacturing Organization (CDMO) services providing pharmaceutical production and manufacturing capabilities to pharmaceutical company clients. Following the February 2023 partial demerger, Sofar S.p.A. focuses exclusively on this service offering.

Segments1 record

Ideal customer profiles1 record

Technology focussed No

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Recent moves3 records

Expansion highlights1 record

Direct peers

• Recipharm: European-headquartered CDMO offering solid-dose, sterile, and API manufacturing services to pharma clients. Directly comparable to Sofar on geography (Europe), service mix (small-molecule CDMO), and target customer base (mid-market and generics pharma).
• Siegfried Holding: Swiss-listed CDMO providing API and finished drug product manufacturing for branded and generic pharma. Comparable to Sofar in integrated drug-substance/drug-product CDMO scope and European mid-market positioning.
• Aenova Group: German-headquartered CDMO offering solid, semi-solid, sterile, and biologic manufacturing services. Comparable to Sofar on pharmaceutical contract manufacturing focus, European footprint, and broad dosage-form capabilities.
• Fareva: Privately-held French CDMO providing API, drug product, and packaging services to pharmaceutical clients. Comparable to Sofar in private mid-sized European CDMO profile and broad small-molecule manufacturing scope.
• Delpharm: French CDMO offering contract manufacturing of solid, liquid, sterile, and biologic drug products for European pharma sponsors. Comparable to Sofar on European generics-focused CDMO positioning and similar mid-market scale.
• BSP Pharmaceuticals: Italian CDMO specializing in sterile injectable and oncology product manufacturing. Closely comparable to Sofar on Italian geography, pharmaceutical contract manufacturing, and similar mid-sized European CDMO profile.
• Olon Group: Italian API manufacturer and CDMO with a strong generics-focused small-molecule portfolio. Comparable to Sofar in Italian origin, API and drug-product CDMO capabilities, and service to generics pharma sponsors.
• Corden Pharma: Global CDMO offering API synthesis, drug product manufacturing, and packaging across multiple modalities. Comparable to Sofar in integrated small-molecule CDMO scope, though operating at a larger scale.

Broad incumbents

• Alfasigma S.p.A. Parent company of Sofar S.p.A. and an Italian specialty pharmaceutical group with both proprietary branded products and contract manufacturing activities. Comparable as both the strategic owner and an adjacent incumbent in pharmaceutical manufacturing with broader commercial capabilities than Sofar's now-focused CDMO scope.
• Lonza Group: Global CDMO leader offering small-molecule API, biologics, and cell-and-gene therapy manufacturing services. Comparable to Sofar as a CDMO operating in the same end markets, though at vastly greater scale, geographic reach, and modality breadth.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat3 records

Key risks5 records

Key highlights5 records

Customer concentration

Revenue estimate

Valuation estimate

Number of profiles

Profiles2 records

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments1 record

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Sofar